HLB Therapeutics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 49

Employees

  • Stock Symbol
  • 115450

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $1.22
  • (As of Monday Closing)

HLB Therapeutics General Information

Description

HLB Therapeutics Co Ltd is a biotech company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a biopharmaceutical company focused on alleviating patient suffering.

Contact Information

Formerly Known As
GtreeBNT Co., Ltd., Digital Aria Co., Ltd., Digital Aria
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 22F, Parkview Office Tower
  • 248, Jeongjail-ro, Bundang-gu
  • Seongnam, Gyeonggi 13554
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 22F, Parkview Office Tower
  • 248, Jeongjail-ro, Bundang-gu
  • Seongnam, Gyeonggi 13554
  • South Korea
+82

HLB Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HLB Therapeutics Stock Performance

As of 16-Nov-2026, HLB Therapeutics’s stock price is $1.22. Its current market cap is $108M with 88.1M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.22 $1.75 $0.89 - $2.83 $108M 88.1M 689K -$0.14

HLB Therapeutics Financials Summary

As of 30-Jun-2026, HLB Therapeutics has a trailing 12-month revenue of $44.4M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 161,606 188,209 641,486 243,125
Revenue 44,408 48,879 40,260 40,224
EBITDA (11,356) (3,645) (10,154) 4,176
Net Income (12,418) (6,483) (16,705) (1,761)
Total Assets 143,041 158,787 149,218 155,814
Total Debt 26,206 28,160 15,854 7,777
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HLB Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HLB Therapeutics‘s full profile, request access.

Request a free trial

HLB Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HLB Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HLB Therapeutics‘s full profile, request access.

Request a free trial

HLB Therapeutics Investments & Acquisitions (3)

HLB Therapeutics’s most recent deal was a PIPE with HLB Genex for . The deal was made on 12-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HLB Genex 12-Dec-2024 PIPE Drug Discovery
HLB Panagene (Biotechnology) 21-Jun-2023 Merger/Acquisition Biotechnology
HLB Panagene (Biotechnology) 20-Jun-2023 PIPE Biotechnology
To view HLB Therapeutics’s complete investments and acquisitions history, request access »

HLB Therapeutics ESG

Risk Overview

Risk Rating

Updated June, 30, 2025

31.3 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view HLB Therapeutics’s complete esg history, request access »

HLB Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
HLB Panagene (Biotechnology) Daejeon, South Korea 1976

HLB Therapeutics FAQs

  • When was HLB Therapeutics founded?

    HLB Therapeutics was founded in 2000.

  • Where is HLB Therapeutics headquartered?

    HLB Therapeutics is headquartered in Seongnam, South Korea.

  • What is the size of HLB Therapeutics?

    HLB Therapeutics has 49 total employees.

  • What industry is HLB Therapeutics in?

    HLB Therapeutics’s primary industry is Drug Discovery.

  • Is HLB Therapeutics a private or public company?

    HLB Therapeutics is a Public company.

  • What is HLB Therapeutics’s stock symbol?

    The ticker symbol for HLB Therapeutics is 115450.

  • What is the current stock price of HLB Therapeutics?

    As of 16-Nov-2026 the stock price of HLB Therapeutics is $1.22.

  • What is the current market cap of HLB Therapeutics?

    The current market capitalization of HLB Therapeutics is $108M.

  • What is HLB Therapeutics’s current revenue?

    The trailing twelve month revenue for HLB Therapeutics is $44.4M.

  • What is HLB Therapeutics’s annual earnings per share (EPS)?

    HLB Therapeutics’s EPS for 12 months was -$0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process